Third pharmaceutical company at SPAP
On 1 January 2025, iQone will become the third pharmaceutical company to join the Swiss Patient Access Program (SPAP). So far, Roche and AstraZeneca are partner companies of SPAP.
As a reminder, the SPAP was launched by the SSMO to enable cancer patients to gain rapid and equal access to off-label use medications that have previously been rejected twice by health insurance companies.
You are welcome to continue submitting your applications to SPAP here: https://www.spap.health/de/
